Cambridge Healthtech Institute’s 5th Annual

Fusion Protein Therapeutics

Developing and Optimizing Fusion Proteins for Oncology and Beyond

April 8-9, 2019


Chimeric fusion proteins, with their ability to extend plasma half-life and prolong therapeutic activity, offer exciting benefits over antibody-based therapeutics. Companies are intensely investigating into fusion protein therapeutics as a promising alternative to antibodies. The 5th Annual Fusion Protein Therapeutics will explore the latest developments and future prospects of this exciting modality by inviting researchers to present their novel Fc-fusion platforms, present updates from preclinical and clinical trials, and discuss engineering and conjugation strategies to improve efficacy, safety and clinical success.

Preliminary Agenda


Antibody-Cytokine Fusion Proteins: From Discovery to Pivotal Clinical Trials

Dario Neri, PhD, Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich)

Novel Platform Development and Application for Fc-Fusion Proteins

Lu Shan, PhD, Scientist II, ADPE, MedImmune

Redefinition of RTK Tumor Targeting: How to Design Truly Potent anti-ErbB Bispecific and Biparatopic Fusion Therapeutics

Rastislav Tamaskovic, PhD, Head, TC Facility, Biochemistry, University of Zurich

Leveraging FcRn-Blocking Therapeutic Utility for Autoantibody Mediated Disease Through A Minimized Affibody Fusion Format

Fredrik Frejd, PhD, CSO, Affibody


Mechanisms for Half-Life Extension of Therapeutic Proteins by Albumin Fusion

Anne Verhagen, PhD, Director, Protein Biochemistry, CSL Research, CSL Ltd.

Protein Engineering by Directed Evolution to Derive ALPN-101, a Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgD)-Fc Fusion Protein for the Treatment of Inflammatory Diseases

Mark Rixon, PhD, Sr. Director, Protein Therapeutics, Alpine Immune Sciences

Optimization of a Bispecific Anti-CD3 Antibody-Folate Bio-Conjugate for the Treatment of Ovarian Cancer

Harun Rashid, PhD, Sr. Principal Scientist, Molecular Technology, Ambrx


Preconditioning the Tumor Microenvironment to Enable Effective Immunotherapy Using Antibody Fusion Proteins

Alan Epstein, MD, PhD, University of South Carolina

Engineering Hexavalent TNFR-SF Agonists for Cancer Immunotherapy: A Unique Class of Biologics

Oliver Hill, PhD, VP, Molecular Biology/Protein Engineering, Apogenix AG

Development of A Novel Multi-Specific Antibody Targeting PD-L1-Overexpressing Cancers by Engagement of Antigen-Committed CD8+ T-Cells Via the Costimulatory Receptor 4-1BB

Sebastian Meyer, PhD, COO, Numab Innovation AG

Targeting Complex Glycans in the Tumor Microenvironment by GAGbodies

Andreas Kungl, PhD, CEO, Antagonis Biotherapeutics GmbH


Platform Technology for Treatment of The Brain in Lysosomal Storage Disorders with IgG-Fusion Proteins: Pre-Clinical and Clinical Update

Ruben Boado, PhD, VP, R&D and Co-Founder, ArmaGen, Inc.

Next-Generation Antibody-Guided Enzyme Replacement Therapy for Lysosomal Diseases

Katherine Cygnar, PhD, Senior Staff Scientist, Genome Engineering Technologies, Regeneron Pharmaceuticals

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese

Premier Sponsors

View By: